Addendum

Elinzanetant (vasomotor symptoms in menopause) – Addendum to Project A26-34

Report documents

Indication:

Patients with moderate to severe vasomotor symptoms associated with the menopause

Result of dossier assessment:

Patients for whom hormone replacement therapy is an option and who have decided in favour of hormone replacement therapy after an individual risk-benefit assessment: unchanged after addendum: added benefit not proven
Patients for whom hormone replacement therapy is not an option or who have decided against hormone replacement therapy after an individual risk-benefit assessment: unchanged after addendum: added benefit not proven

01-10-2026 A G-BA decision was published.
GBA documents on this decision

Project no.: A26-101
Commission: Commission awarded on 11.08.2026 by the Federal Joint Committee (GBA).
Report type: Addendum
Status: Commission completed
Department/Division: Drug Assessment
Topic: Reproductive health and birth
Note: If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
DOI: https://doi.org/10.60584/A26-101_V1.1

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.